NEXT GENERATION RNA BASED THERAPEUTICS

THE FUTURE OF PD THERAPY; WHY MULTI TARGET DRUGS

 Moussa Youdim (Israel)

CSF AND BLOOD BIOMARKERS FOR AD – PATHOPHYSIOLOGY, DIAGNOSTIC ALGORITHMS AND THERAPY MONITORING

 Kaj Blennow (Sweden)

TRANSLATIONAL NEUROPATHOLOGY: BEGINNING AT THE END TO INFORM THE BEGINNING

 Melissa Murray (USA)

CONSIDERATION OF BLOOD-BASED BIOMARKERS FOR COMMUNITY SCREENING – INFLUENCE OF COMORBIDITIES, RACE/ETHNICITY, AND SEX

 Michelle Mielke (USA)

DISEASE MODIFIERS FOR ALZHEIMER’S DISEASE – A REGULATORY PERSPECTIVE

 Yaning Wang (USA)

THE FIRST DISEASE-MODIFYING TREATMENTS FOR AD: A GLASS HALF FULL

 Denis Selkoe (USA)